Since the outbreak of novel coronavirus pneumonia in December，2019，the Extracorporeal Membrane Oxygenation （ECMO），as an advanced form of life support mechanism，has played a vital role in the treatment of critical patients and has been attracting sustained attention thereof. Along with the improvement of technological development and the enhancement of capacity for medical payment by patients，the past few years has witnessed the tremendous increase in the number of clinical application cases and that of clinical institutions capable of carrying out ECMO therapy，and the investment in R&D and technology input for ECMO has been increasing accordingly. The significant role of ECMO during the outbreak of NCIP has made the government and enterprises realize the importance of domestic development of ECMO industry independently. Despite of the late-start of ECMO industry，weakness in brand image，and lack of core technologies in China，the therapy level of ECMO clinical application in China is being geared to international standards after years of technology accumulation，and domestic R&D teams and enterprises have achieved tremendous breakthrough in ECMO equipment R&D. This paper will analyze the clinical application status of ECMO in China during NCIP from the following perspectives such as clinical application scenarios and application status of ECMO technology，the application of ECMO during NCIP，the core technologies and its barriers，and technology development trends. Moreover，the prospects for future development will be outlined.